Argent Biopharma Ltd · ASX:RGT
Argent Biopharma — MGC Pharmaceuticals — Investor Presentation (May 2015)
15 slides from Argent Biopharma's investor presentation, May 21, 2015
Slide 1: Investment in MGC Pharmaceuticals
Investment in MGC Pharmaceuticals Investor Presentation May 2015
Slide 2: Disclaimer
Disclaimer This presentation has been prepared by Erin Resources Limited (“Company”). It does not purport to contain all the information that a prospective investor may require in connection with any potential investment in the Company. You should not treat the contents of this presentation, or any
Slide 3: Transaction Overview
Transaction Overview Erin Resources Limited has entered into a binding heads of agreement under which it has the exclusive option to acquire 100% of the issued capital in MGC Pharmaceuticals Ltd (MGC), an Israeli based medical and cosmetic cannabis company Capital Structure − post MGC acquisition Or
Slide 4: Company Overview MGC Pharmaceuticals
Company Overview MGC MGC Pharmaceuticals Limited (MGC), is an Israeli medical and cosmetic cannabis company with Pharmaceuticals collectively over 40 years of technical and commercial experience in the medical and cosmetics cannabis Capitalizing on brand Israel – industry world leaders in the produc
Slide 5: Investment Highlights
Investment Highlights • Strategically positioned to exploit the rapidly growing demand for medical cannabis (worth US$2.7bn) and CBD in the cosmetic (cosmetic market globally estimated at US$270 b and $70 b in Europe in 2014) • Unique genetics from exclusive strain of Cannabis Sativa comprising very
Slide 6: Industry Leading Expertise and Experience
Industry Leading Expertise and Experience Nativ Segev Roby Zomer Mr. Yaron Blubshtin Co-Founder and Co-Founder and Director of Chief Agronomist / Managing Director Business Development Advisor Nativ Segev was the CEO of Mr. Zomer brings a wealth of Yaron Blubshtin holds over 45 Israel’s second large
Slide 7: Key Milestones
Key Milestones Completion of license to grow and extract CBD resin in the EU - Q3 2015 Secure commercial offtake agreement with a EU distributor to supply CBD Resin Q3 2015 Establishment of growing operation and planting of first crop - H2 2015 Joint Venture agreement for R&D - H2 2015 First harvest
Slide 8: Business Development Activities and Pipeline
Business Development Activities and Pipeline Register genetic Begin first First revenues bank in Israel cultivation and from off-take and the EU extraction agreement Q3 2015 H1 2016 H2 2016 H2 2015 H1 2016 Q1 2017 Establish Establish growing Apply for and growing protocols and obtain outdoor operati
Slide 9: Global Market Opportunity
Global Market Opportunity • Cannabinoids are legal in 23 U.S states and the MC market is estimated to be worth USD$2.7 billion globally in 2014 and US$10 billion by 2019 • In Canada the market for medical cannabis is expected to grow significantly, from $144m in 2014 • Common diseases for which Cann
Slide 10: CBD Global Market Opportunity − Cosmetics
CBD Global Market Opportunity − Cosmetics • In 2013 the cosmetics industry was worth US$270 billion - over 100 times that of the medical marijuana industry for 2014. • CBD resins used increasingly as base product in the cosmetics industry • The skin care market is estimated to account for 37% of the
Slide 11: Cannabidiol (CBD) – Global Potential
Cannabidiol (CBD) – Global Potential • Found only in cannabis plants, Cannabidiol (CBD) is the non- psychoactive ingredient • Impacts pathways in the body, which control pain and support the immune system, thereby delivering significant medicinal benefits in the treatment of chronic pain • It has a
Slide 12: High CBD Cannabis Sativa
High CBD Cannabis Sativa Wider Market Legality CBD Cannabis Sativa legally produced - under Cannabis license Legal in 23 states in the U.S 21/05/2015 12
Slide 13: CBD Market Expected to Grow
CBD Market Expected to Grow US$ millions Canada U.S Europe Canada 10.2 10 CAGR +30% 6.8 U.S CAGR +45% Europe 2.3 CAGR +10% 0.6 0.2 E2014 E2018 21/05/2015 13
Slide 14: Strategic and Focused Business Plan
Strategic and Focused Business Plan Licensing Register Good License strains and Register High CBD Manufacturing guidelines to growing strains in Europe Practice (GMP) operations in Europe First revenues via off- Growing Establish Sativa take agreements of Apply for additional Growing operation in fi
Slide 15: Investment Summary
Investment Summary • Strategically positioned to exploit the rapidly growing demand for medical cannabis (worth US$2.7bn) and CBD in the cosmetic (cosmetic market globally estimated at US$270 b and $70 b in Europe in 2014) • Unique genetics from exclusive strain of Cannabis Sativa comprising very lo
MGC Pharmaceuticals — Investor Presentation (May 2015) on 6ix